SOURCE: Gene Express, Inc.

March 20, 2006 08:30 ET

Gene Express to Attend R&D Leaders Forum for Senior Pharmaceutical and Biotechnology Executives

TOLEDO, OH -- (MARKET WIRE) -- March 20, 2006 -- Gene Express, Inc. today announced that Chairman, Alfred Pollock and CEO, Gerald Vardzel will attend the R&D Leaders' Forum Spring 2006 conference in Coral Gables, Florida on March 20-22. Gene Express will also host a corporate booth at the forum featuring its StaRT-PCR™ platform technology for measuring gene expression.

The forum is designed to provide an open environment for senior-level knowledge exchange around solutions to the healthcare industry's core research and development challenges. Featured speakers include senior executives from prominent drug development companies such as AstraZeneca, Bristol-Meyers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Pfizer, Sanofi-Aventis, Schering-Plough, and others.

The three-day agenda covers many critical issues including: comparison of approaches to systems redesign for discovery optimization, thought leadership on target validation and the impact of combining genomics and experimental medicine, debates on how the big pharma research and development business model will integrate targeted and personalized medicine, quantification of the impact of new technologies on reducing attrition and increasing quality and safety and discussions on the latest issues in regulation, routes to market and economics of novel oncology therapies.

Mr. Vardzel stated, "The R&D Leaders' Forum will provide us with great opportunities for networking with the highest levels of research and development management across the pharmaceutical and biotechnology sectors. We look forward to further informing these constituencies about how our StaRT-PCR™ technology can accelerate progress and reduce cost in the research and development process."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcriptase Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, tissue and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information

  • Contact:
    Rachel Levine
    The Global Consulting Group
    Tel: 646-284-9439
    E: Email Contact